Peel Hunt restated their add rating on shares of Circassia Pharmaceuticals PLC (LON:CIR) in a report released on Tuesday morning. They currently have a GBX 160 ($2.09) price objective on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently issued reports on CIR. Numis Securities Ltd restated an under review rating on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. Stifel Nicolaus restated a buy rating and set a GBX 375 ($4.89) price target on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. JPMorgan Chase & Co. decreased their price target on shares of Circassia Pharmaceuticals PLC from GBX 410 ($5.35) to GBX 170 ($2.22) and set an overweight rating for the company in a report on Tuesday, June 21st. Royal Bank Of Canada lowered shares of Circassia Pharmaceuticals PLC to a sector performer rating and cut their price objective for the company from GBX 430 ($5.61) to GBX 105 ($1.37) in a research report on Tuesday, June 21st. Finally, Barclays PLC started coverage on shares of Circassia Pharmaceuticals PLC in a research report on Tuesday, June 21st. They set an overweight rating and a GBX 170 ($2.22) price objective for the company. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Circassia Pharmaceuticals PLC presently has an average rating of Buy and an average target price of GBX 183.33 ($2.39).
Circassia Pharmaceuticals PLC (LON:CIR) opened at 94.25 on Tuesday. The stock’s 50 day moving average price is GBX 94.47 and its 200 day moving average price is GBX 177.88. Circassia Pharmaceuticals PLC has a 12 month low of GBX 81.05 and a 12 month high of GBX 322.90. The firm’s market capitalization is GBX 268.51 million.
About Circassia Pharmaceuticals PLC
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.